This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Rimage Elects Justin A. Orlando Of Dolphin Limited Partnerships To Its Board Of Directors

Rimage Corporation (NASDAQ: RIMG) today announced that it has elected Justin A. Orlando to its Board of Directors, effective immediately. Mr. Orlando is a managing director of Dolphin Limited Partnership III, L.P. (“Dolphin”), a Stamford, CT based private investment concern established in 1996, where he has worked since 2002. Mr. Orlando’s election brings the total number of directors on the Rimage board to eight.

Prior to joining Dolphin, Mr. Orlando was a member of the healthcare investment banking group of Merrill Lynch, Pierce, Fenner & Smith Incorporated where he was involved in advisory work, financings, and control transactions from 1999 to 2002. From 1996 to 1999, Mr. Orlando practiced corporate law with the law firm of Paul, Weiss, Rifkind, Wharton & Garrison LLP, focusing on mergers and acquisitions and corporate finance transactions.

Sherman L. Black, president and CEO, said, “We are pleased to welcome Justin Orlando to the Rimage Board. Justin brings a deep level of investing experience and provides our board with the perspective of a large shareholder through his affiliation with Dolphin.”

Mr. Orlando’s election to the Board of Directors was made pursuant to an agreement between Rimage and Dolphin. Dolphin holds approximately 6.5% of Rimage’s outstanding shares. The agreement between Rimage and Dolphin will be included as an exhibit to the Company's Current Report on Form 8-K that will be filed with the Securities and Exchange Commission (“SEC”). Mr. Orlando will also be a nominee for election to the Board of Directors at the Company’s 2013 Annual Meeting of Shareholders. Further details regarding the Company’s 2013 Annual Meeting of Shareholders will be included in the Company’s definitive proxy materials, which will be filed with the SEC.

A spokesperson for Dolphin indicated, “Dolphin is pleased to have a meaningful investment in Rimage and to be given the opportunity to work with the Rimage Board to generate value for shareholders.”

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs